| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Denosumab |
| Brand | Xgeva® |
| Indication | For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland |
| Assessment Process | |
| Full HTA commissioned by the HSE | 15/08/2011 |
| NCPE assessment completed | 08/12/2011 |
| NCPE assessment outcome | Denosumab (Xgeva®) is considered a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting. |